Hidenori Nakagawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hidenori Nakagawa has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Michinori Shirano
Department of Infectious Diseases, Osaka City General Hospital, Osaka, Japan
4 shared publications- Keiji Konishi
AIDS Medical Center, NHO Osaka National Hospital, Osaka, Japan
2 shared publications - Masato Nishihara
Department of Pediatrics, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashiyodogawa-ku, Osaka-shi, Osaka, 533-0024, Japan
2 shared publications - Michinori Shirano
Department of Infectious Diseases, Osaka City General Hospital
2 shared publications Akari Takagi
Department of Neurology, Osaka City General Hospital, Osaka, Japan
1 shared publicationAkihiro Manabe
Department of Clinical Laboratory Medicine, Fukuyama City Hospital, Fukuyama, 721-8511, Japan
1 shared publication
Latest Publications
- Open Access
- 3 November 2025
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 92  (11) , 654-655
Multiple scabietic nodules on the scrotum in a patient living with HIV infection
- 3 November 2025
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 92  (11) , 654-655
Open AccessMultiple scabietic nodules on the scrotum in a patient living with HIV infection
- Open Access
- 1 April 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64  (7) , 1129-1130
A Pharyngeal Papillary Lesion of Syphilis
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 1 April 2025
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 64  (7) , 1129-1130
Open AccessA Pharyngeal Papillary Lesion of Syphilis
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 18 August 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29  (12) , 1137-1144
Characteristics of preventive intervention acceptance for international travel among clients aged 60 years and older from a Japanese multicenter pretravel consultation registry
- 18 August 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29  (12) , 1137-1144
Open AccessCharacteristics of preventive intervention acceptance for international travel among clients aged 60 years and older from a Japanese multicenter pretravel consultation registry
- Open Access
- 22 December 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 18  (3) , 903-906
Life-threatening pneumothorax after release from isolation with COVID-19 pneumonia
- 22 December 2022
- Published by Elsevier in Radiology Case Reports
- Vol. 18  (3) , 903-906
Open AccessLife-threatening pneumothorax after release from isolation with COVID-19 pneumonia
- Open Access
- 21 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101  (42) , e31349
Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition
To investigate the prevalence of sarcopenia among people living with HIV (PLWH) in Japan and analyze the relationship between HIV infection and ART effects on the body composition of Japanese PLWH for more appropriate drug selection and lifestyle guidance. Cross-sectional observational study. We included male patients aged ≥ 60 years whose body composition was measured by InBody 570 body composition analyzer during outpatient visits. Patients were classified by body shape based on body mass index (BMI) and body fat percentage measurements and by tenofovir alafenamide administration. Hidden obesity is a condition wherein the BMI is within the standard range but the body fat percentage is higher than the reference. Patients with low muscle mass and strength were considered to have sarcopenia, whereas those with only low muscle strength were considered to have pre-sarcopenia. In total, 87 patients were included. Based on body shape determined by BMI and body fat percentage, most patients had hidden obesity (40 patients, 46.0%). Sarcopenia was detected in 9 patients (10.3%) and pre-sarcopenia in 14 patients (16.1%). The tenofovir alafenamide (TAF) use group had significantly higher BMI, higher skeletal muscle mass, body fat mass, and skeletal muscle mass index relative to the non-TAF use group. Hidden obesity is a risk for lifestyle diseases. It is important to recognize it based on body composition measurements because it can be missed by BMI measurement alone. Tenofovir alafenamide therapy increases skeletal muscle mass, which may result in the prevention of sarcopenia. To clarify how TAF affects the development of sarcopenia and lifestyle diseases, future studies on a larger cohort are warranted.
- 21 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101  (42) , e31349
Open AccessSarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition
To investigate the prevalence of sarcopenia among people living with HIV (PLWH) in Japan and analyze the relationship between HIV infection and ART effects on the body composition of Japanese PLWH for more appropriate drug selection and lifestyle guidance. Cross-sectional observational study. We included male patients aged ≥ 60 years whose body composition was measured by InBody 570 body composition analyzer during outpatient visits. Patients were classified by body shape based on body mass index (BMI) and body fat percentage measurements and by tenofovir alafenamide administration. Hidden obesity is a condition wherein the BMI is within the standard range but the body fat percentage is higher than the reference. Patients with low muscle mass and strength were considered to have sarcopenia, whereas those with only low muscle strength were considered to have pre-sarcopenia. In total, 87 patients were included. Based on body shape determined by BMI and body fat percentage, most patients had hidden obesity (40 patients, 46.0%). Sarcopenia was detected in 9 patients (10.3%) and pre-sarcopenia in 14 patients (16.1%). The tenofovir alafenamide (TAF) use group had significantly higher BMI, higher skeletal muscle mass, body fat mass, and skeletal muscle mass index relative to the non-TAF use group. Hidden obesity is a risk for lifestyle diseases. It is important to recognize it based on body composition measurements because it can be missed by BMI measurement alone. Tenofovir alafenamide therapy increases skeletal muscle mass, which may result in the prevention of sarcopenia. To clarify how TAF affects the development of sarcopenia and lifestyle diseases, future studies on a larger cohort are warranted.
- Open Access
- 29 November 2021
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 18  (1) , 1-5
Protein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report
Background: Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced human immunodeficiency virus (HIV) infection. Effective antiretroviral therapy has dramatically reduced the incidence of and mortality due to HIV infection, although drug resistance and poor medication adherence continue to increase the risk of disseminated M. avium complex infection. However, gastrointestinal lesions in cases of disseminated M. avium complex infection resulting in protein-losing enteropathy have been rarely discussed. Therefore, we present a case of protein-losing enteropathy caused by disseminated M. avium complex infection in a patient undergoing antiretroviral therapy. Case presentation: A 29-year-old man was diagnosed with AIDS 4 years ago and was admitted for a 10-month history of refractory diarrhea and fever. Despite receiving antiretroviral therapy, the viral load remained elevated due to poor medication adherence. The patient was diagnosed with disseminated M. avium complex infection and started on antimycobacterial drugs 2 years before admission. However, the infection remained uncontrolled. The previous hospitalization 1 year before admission was due to hypoalbuminemia and refractory diarrhea. Upper gastrointestinal endoscopy revealed a diagnosis of protein-losing enteropathy caused by intestinal lymphangiectasia, and treatment with intravenous antimycobacterial drugs did not resolve his intestinal lymphangiectasia. The patient inevitably died of sepsis. Conclusions: Clinical remission is difficult to achieve in patients with AIDS and protein-losing enteropathy caused by disseminated M. avium complex infection due to limited options of parenteral antiretroviral drugs. This report highlights the importance of identifying alternative treatments (such as an injectable formulation) for patients who do not respond to antiretroviral therapy due to protein-losing enteropathy with disseminated M. avium complex infection.
- 29 November 2021
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 18  (1) , 1-5
Open AccessProtein-losing enteropathy caused by disseminated Mycobacterium avium complex infection in a patient receiving antiretroviral therapy: an autopsy case report
Background: Disseminated Mycobacterium avium complex infection is an important indicator of acquired immunodeficiency syndrome (AIDS) in patients with advanced human immunodeficiency virus (HIV) infection. Effective antiretroviral therapy has dramatically reduced the incidence of and mortality due to HIV infection, although drug resistance and poor medication adherence continue to increase the risk of disseminated M. avium complex infection. However, gastrointestinal lesions in cases of disseminated M. avium complex infection resulting in protein-losing enteropathy have been rarely discussed. Therefore, we present a case of protein-losing enteropathy caused by disseminated M. avium complex infection in a patient undergoing antiretroviral therapy. Case presentation: A 29-year-old man was diagnosed with AIDS 4 years ago and was admitted for a 10-month history of refractory diarrhea and fever. Despite receiving antiretroviral therapy, the viral load remained elevated due to poor medication adherence. The patient was diagnosed with disseminated M. avium complex infection and started on antimycobacterial drugs 2 years before admission. However, the infection remained uncontrolled. The previous hospitalization 1 year before admission was due to hypoalbuminemia and refractory diarrhea. Upper gastrointestinal endoscopy revealed a diagnosis of protein-losing enteropathy caused by intestinal lymphangiectasia, and treatment with intravenous antimycobacterial drugs did not resolve his intestinal lymphangiectasia. The patient inevitably died of sepsis. Conclusions: Clinical remission is difficult to achieve in patients with AIDS and protein-losing enteropathy caused by disseminated M. avium complex infection due to limited options of parenteral antiretroviral drugs. This report highlights the importance of identifying alternative treatments (such as an injectable formulation) for patients who do not respond to antiretroviral therapy due to protein-losing enteropathy with disseminated M. avium complex infection.
- Open Access
- 31 October 2021
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 9  (2) , e0046021
Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients
We evaluated vancomycin pharmacokinetics in pediatric LT recipients and developed a population pharmacokinetics model by considering various factors that might account for alterations in vancomycin pharmacokinetics. Our analyses revealed that lower serum creatinine levels and a shorter duration from the day of LT were associated with higher vancomycin clearance and led to subtherapeutic drug exposure.
- 31 October 2021
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 9  (2) , e0046021
Open AccessPopulation Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients
We evaluated vancomycin pharmacokinetics in pediatric LT recipients and developed a population pharmacokinetics model by considering various factors that might account for alterations in vancomycin pharmacokinetics. Our analyses revealed that lower serum creatinine levels and a shorter duration from the day of LT were associated with higher vancomycin clearance and led to subtherapeutic drug exposure.
- 29 July 2019
- Published by Wiley in Pediatrics International
- Vol. 61  (7) , 738
Bromoderma in a child with refractory epilepsy
- 29 July 2019
- Published by Wiley in Pediatrics International
- Vol. 61  (7) , 738
Bromoderma in a child with refractory epilepsy